DataMeds AI shareholders approve 1,000,000 blank-check preferred shares
MEDS•DataMeds AI shareholders approved a charter amendment authorizing 1,000,000 blank-check preferred shares and common stock issuances to Silverback Capital beyond Nasdaq’s 20% threshold. They also reelected five directors and ratified Suri & Co. as auditor for fiscal 2026.
1. Shareholders approve actions
DataMeds AI shareholders adopted four corporate actions by written consent dated August 25, 2026. They authorized 1,000,000 blank-check preferred shares and common stock issuances to Silverback Capital under a January 28, 2026, settlement agreement beyond Nasdaq’s 20% threshold.
2. Directors and auditor
Shareholders reelected five incumbent directors to serve until the 2027 annual meeting and ratified Suri & Co. as independent auditor for the fiscal year ending December 31, 2026.
